{"id":989608,"date":"2026-08-04T16:10:53","date_gmt":"2026-08-04T20:10:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-reports-second-quarter-2026-financial-results-and-provides-business-update\/"},"modified":"2026-08-04T16:10:53","modified_gmt":"2026-08-04T20:10:53","slug":"syndax-reports-second-quarter-2026-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-reports-second-quarter-2026-financial-results-and-provides-business-update\/","title":{"rendered":"Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n \u2013 Total revenue of $73 million in 2Q26, a 92% year-over-year increase \u2013<\/em>\n <\/p>\n

\n \u2013 Revuforj<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase \u2013<\/em>\n <\/p>\n

\n \u2013 Niktimvo\u2122 (axatilimab-csfr) net revenue of $60.3 million in 2Q26, a 67% year-over-year increase, resulting in Syndax collaboration revenue of $18.1 million \u2013<\/em>\n <\/p>\n

\n \u2013 Expanded pipeline with a novel, mutant-selective, allosteric EGFR inhibitor for NSCLC and an internally developed next-generation menin inhibitor for myelofibrosis \u2013<\/em>\n <\/p>\n

\n \u2013 Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD \u2013<\/em>\n <\/p>\n

\n \u2013 Company to host a conference call today at 4:30 p.m. ET \u2013<\/em>\n <\/p>\n

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today reported its financial results for the second quarter ended June 30, 2026, and provided a business update.<\/p>\n

\u201cWe delivered another quarter of strong commercial results, with both our medicines now annualizing at well over $200 million each and positioned for further growth,\u201d said Michael A. Metzger, Chief Executive Officer. \u201cNotably, we achieved $55 million in Revuforj net revenue and the sixth consecutive quarter of double-digit net revenue and prescription growth, highlighting our leadership in menin inhibition, robust demand in both NPM1 and KMT2A, and an increasing average treatment duration. Niktimvo net revenue grew to $60 million this quarter, underscoring the benefits of its unique mechanism of action in cGVHD and the substantial commercial opportunity.\u201d<\/p>\n

Mr. Metzger continued, \u201cWe\u2019ve made excellent progress advancing our growing pipeline targeting multiple blockbuster opportunities, including two recently announced assets with first- and best-in-class potential in EGFR-mutated NSCLC and myelofibrosis. We are positioned to be first to frontline AML with Revuforj, driven by strong global site initiation and patient enrollment in our pivotal trials. We also have multiple near-term catalysts with Niktimvo Phase 2 data in IPF and frontline cGVHD expected in the fourth quarter, plus additional practice-informing and potentially guideline-enabling Revuforj data in acute leukemia.\u201d<\/p>\n

\n Recent Business Highlights and Anticipated Milestones<\/strong>\n <\/p>\n

\n Revuforj<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n (revumenib) <\/strong>\n <\/p>\n